AcelRx Pharmaceuticals, Inc. Aktie News

Die NEPHRO-CRRT-Studie zur klinischen Prüfung von nafamostat ist zu 75 % eingeschrieben; Abschluss wird noch dieses Jahr erwartet Der Entwurf der KDIGO-Leitlinien 2026 nahm nafamostat als akzeptables CRRT-Antikoagulans auf, eine positive Änderung gegenüber früheren Leitlinien Aktualisierte Marktforschung schätzt jährlich 200.000 CRRT-Verfahren in den USA, ein Anstieg um 21 % gegenüber vorherige...

NEPHRO CRRT clinical study expected to be completed this year Cash and investments of $21.1 million at March 31, 2026 Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET SAN MATEO, Calif., May 13, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...

SAN MATEO, Calif., May 7, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2026 financial results after market close on Wednesday, May 13, 2026, then host a live webcast and confe...

SAN MATEO, Calif., March 25, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the acceptance of two abstracts for presentation at the 31st Annual International Conference on Advances in Critical Care Nephrology: AK...

Previously announced achievement of 50% enrollment of the NEPHRO CRRT clinical study in March 2026 and closed the associated financing tranche of $4.1 million All 12 clinical study sites now able to enroll patients to support an expected study completion in 2026 Cash and investments of $20.4 million at December 31, 2025 Virtual investor and analyst day with business updates to be held on Monday...